Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed
Executive Summary
FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval
You may also be interested in...
Replagal Advisory Committee Will Include Closed Door Session On Manufacturing
FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.
Insmed Seeks To Block Tercica Growth Hormone In Orphan Exclusivity Fight
A battle for orphan drug exclusivity may be at the heart of a dispute between Insmed and Tercica over the companies' pending NDAs for growth hormone treatments
Insmed Seeks To Block Tercica Growth Hormone In Orphan Exclusivity Fight
A battle for orphan drug exclusivity may be at the heart of a dispute between Insmed and Tercica over the companies' pending NDAs for growth hormone treatments